We noted a physiological plateau phase for horizontal and vertical saccade velocity at higher amplitudes in the control group and for horizontal saccades in the anti-IgLON5 group as well as significant differences between patients suffering from PSP and the other groups (see Figure 1). The gene discussed is IGLON5; the disease is supranuclear palsy, progressive, 1.